Owing to its human and mouse cross-reactivity, we investigated 89Zr-DFO-Atezolizumab in immunodeficient human GBM and immunocompetent murine GBM models for PD-L1 detection in tumors and healthy tissues to complement its utility in the clinical setting. The gene discussed is CD274; the disease is glioblastoma.